A Postmarketing Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With Iclusig® in Routine Clinical Practice in the United States (US).
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- Acronyms OMNI
- Sponsors ARIAD Pharmaceuticals
- 02 Jun 2017 The primary analysis will be performed 12 mo after last patient enrolled and will estimate the incidence of VOEs by duration of ponatinib exposure as per trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 25 Jan 2016 Planned End Date changed from 1 Oct 2019 to 1 Jun 2019 as reported by ClinicalTrials.gov.